Insight

Discover insight from our renowned speakers and Advisory Board members ahead of the inaugural Real-World Evidence 2022: Rare Diseases and Innovative Therapies meeting. Access exclusive interviews, editorials, journal pieces and more!

2022 interviews:

Real-World Evidence 2022: a sneak peek interview with Alexander Schacht

“Launching promotional activities focusing on certain diseases, helped by providing relevant evidence, has become more important over time. The time where patients could not get access to treatment data has passed. It’s time to embrace this change and manage it properly.”

Read the full interview on The Evidence Base now >>

2020 interviews:

Meet the speakers: 5 minutes with Alastair Kent

“Until relatively recently, ‘rare’ was synonymous with ‘not many affected, so not much could be done’, and therefore ‘probably not very important’.”

“…by bringing together families with rare diseases, we have realized that they represent a huge health issue, not just for those affected, but for the health service as a whole. Building that critical mass of affected individuals has both enabled research and facilitated the development of services.”

Read the full interview on The Evidence Base now >>

Meet the speakers: 5 minutes with Paolo Morgese

“Real-world evidence, the infrastructure and methods to generate, collect and use it, represent the present and the future of innovative healthcare. Without a robust and reliable real-world evidence ecosystem, timely access to advanced therapies will be very challenging and will impose a high burden on society.”

“Without real-world evidence, the choice for access bodies will be between taking ill-informed decisions and not taking decisions, which are practically equivalent.”

Read the full interview on The Evidence Base now >>

Meet the speakers: 5 minutes with Maya Zlatanova

“When designing a clinical trial, one must go through protocol development; I have personally witnessed clinical trial protocols structured in such a way that it means that practically no eligible patient exists for trial participation – when we combine indication with eligibility criteria – or that the clinical trial schedule is absolutely impossible to comply with if you are a patient with pain, living far from the trial site, working, have kids etc. This calls for urgent patient and caregiver engagement in clinical trial design.”

“I am excited to see people finally sit together and really try to overcome challenges together because they understand that if we don’t do it together, then it won’t ever happen.”

Read the full interview on The Evidence Base now >>

Articles published in the Journal of Comparative Effectiveness Research: